Direct oral anticoagulants or vitamin K antagonists after TAVR: A systematic review and meta-analysis.

[1]  A. Kosinski,et al.  Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry , 2021, Journal of the American Heart Association.

[2]  C. Hengstenberg,et al.  Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. , 2021, The New England journal of medicine.

[3]  B. Iung,et al.  TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist? , 2021, JACC. Cardiovascular interventions.

[4]  K. Takagi,et al.  Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR. , 2020, JACC. Cardiovascular interventions.

[5]  P. Stella,et al.  Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.

[6]  J. Tijssen,et al.  Rivaroxaban after transcatheter aortic valve replacement: the GALILEO trial. , 2020, Cardiovascular research.

[7]  T. Kuno,et al.  Meta-analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists After Transcatheter Aortic Valve Implantation. , 2020, The American journal of cardiology.

[8]  J. Tijssen,et al.  A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.

[9]  L. Køber,et al.  Vitamin K Antagonists versus Direct Oral Anticoagulants After Transcatheter Aortic Valve Implantation in Atrial Fibrillation. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[10]  A. Colombo,et al.  Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[11]  M. Dalby,et al.  Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry , 2019, Journal of Thrombosis and Thrombolysis.

[12]  Angelo B. Biviano,et al.  Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. , 2019, JACC. Cardiovascular interventions.

[13]  J. Mehilli,et al.  Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. , 2019, JACC. Cardiovascular interventions.

[14]  H. Thiele,et al.  Continued Versus Interrupted Oral Anticoagulation During Transfemoral Transcatheter Aortic Valve Implantation and Impact of Postoperative Anticoagulant Management on Outcome in Patients With Atrial Fibrillation. , 2019, The American journal of cardiology.

[15]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[16]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[17]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[18]  J. Piccini,et al.  Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. , 2018, JACC. Cardiovascular interventions.

[19]  L. Uhlmann,et al.  NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation , 2018, Clinical Research in Cardiology.

[20]  B. Gersh,et al.  Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis. , 2017, American heart journal.

[21]  W. Rottbauer,et al.  Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. , 2017, JACC. Cardiovascular interventions.

[22]  G. Tarantini,et al.  Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome , 2016, European heart journal.

[23]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[24]  G. Gerosa,et al.  Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the SOURCE XT Prospective Multicenter Registry. , 2016, JACC. Cardiovascular interventions.

[25]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[26]  Xian-tao Zeng,et al.  The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic review , 2015, Journal of evidence-based medicine.

[27]  M. Mack,et al.  Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. , 2014, Journal of the American College of Cardiology.

[28]  Maurice Buchbinder,et al.  Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.

[29]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[30]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[31]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[32]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[33]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[34]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[35]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[36]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[37]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[38]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[39]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[40]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[41]  OUP accepted manuscript , 2022, European Heart Journal.

[42]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.